Driving Advancements in Biopharmaceutical Manufacturing

PAK BioSolutions Raises $12 Million Series A to Expand Continuous Biomanufacturing Product Line

17 Jun 2024

Vienna, VA: Today, PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts for its line of automated continuous manufacturing systems for biologics.

The PAK Pilot System is capable of processing 50-500L of cell culture per day, addressing a major segment of the biopharmaceutical production market. With this new financing, PAK will launch its PAK PD benchtop system for lower volume applications, processing 2-10 liters of cellular material per day, and the PAK K-Series system for large-scale commercial manufacturing of 20,000+ liters of material per day. Creation of these systems has required significant R&D resources to address the specific fluid dynamics of each process scale.

“Our expert team of engineers and scientists have worked tirelessly to create new technologies that will enable bioprocess intensification across a breadth of modalities including mAbs, vaccines, recombinant proteins, viral vectors and others. Today is a very exciting day,” said PAK BioSolutions CEO, Joanna Pezzini.

Founded in 2019 by Joanna Pezzini and Kevin Hill-Byrne (CTO), PAK BioSolutions has experienced rapid growth by helping customers achieve a 90% reduction in operator time, 75% reduction in floorplan footprint, and 60% reduction in capital costs compared to traditional biomanufacturing set-ups.

“We have created an out-of-the-box solution, saving biomanufacturing facilities years of development work,” said PAK Co-Founder and CTO, Kevin Hill-Byrne.

“Bringing these new systems to market will revolutionize the field of automated continuous processing for biologics,” said Dan Kidle, who led the investment on behalf of Arboretum and joined PAK’s Board of Directors. “We strive to support technologies that reduce cost and improve quality and have seen an overwhelming response to PAK’s systems.”

The PAK Pilot System won the Interphex Biotech Innovation Award in 2023 and has continually caught the eye of leaders in the industry. End-to-end continuous manufacturing systems for biopharmaceuticals have been gaining interest and entering the GMP manufacturing space. This demand is driven by over 4X productivity improvements, streamlined operations, and a lower risk profile for manufacture and scale-up. To achieve this, all stages of the purification process are operated simultaneously at steady-state.

About PAK BioSolutions

PAK BioSolutions is an early-stage biotechnology company that provides comprehensive solutions for end-to-end continuous manufacture of biopharmaceuticals.  The company aims to meet growing demand for automated equipment and consumables in this space to enable implementation of continuous processes in both laboratory and GMP facilities.

The company’s key technologies include the PAK Pilot, an automated system that operates four continuous purification stages simultaneously, and a solid single-use flow kit that is used with the system.  PAK BioSolutions was awarded its first patent on March 31, 2021 for a “Therapeutic Protein Flow Kit for a Continuous Purification System” by the U.S. Patent and Trademark Office (USPTO), U.S. patent 10,981,950.

In addition to the company’s product offerings, consulting services are provided. PAK’s engineers are available to provide technical seminars, perform individualized technical and business case evaluations, and assist customers with implementation of continuous manufacturing processes.

Recent Posts

NOW AVAILABLE Pilot Scale PAK System

Demo, lease or purchase The PAK System continuous manufacturing equipment. Receive your custom quote now.

Request quote